Innovation
Bringing innovation to patients, better and faster
We're harnessing the power of advanced tech, combined with our deep understanding of the science of the immune system, to develop new medicines and vaccines.
Behind the science US edition
Investors
We announced our second quarter 2026 results on Tuesday, 28 July.
Press releases
- Jemperli (dostarlimab-gxly) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
- Blenrep assigned permanent billing code, supporting timely access for patients with relapsed/refractory multiple myeloma
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
GSK Global links
Visit our Global site for additional features